Drug resistance is a major hurdle in oncology. Responses of acute myeloid leukaemia (AML) patients to cytarabine (Ara-C)-based therapies are often short lived with a median overall survival of months [1] [2] [3] [4] . Therapies are under development to improve outcomes and include targeting the eukaryotic translation initiation factor (eIF4E) with its inhibitor ribavirin [5] [6] [7] . In a Phase II clinical trial in poor prognosis AML 5 , ribavirin monotherapy yielded promising responses including remissions; however, all patients relapsed. Here we identify a novel form of drug resistance to ribavirin and Ara-C. We observe that the sonic hedgehog transcription factor glioma-associated protein 1 (GLI1) and the UDP glucuronosyltransferase (UGT1A) family of enzymes are elevated in resistant cells. UGT1As add glucuronic acid to many drugs, modifying their activity in diverse tissues 8 . GLI1 alone is sufficient to drive UGT1A-dependent glucuronidation of ribavirin and Ara-C, and thus drug resistance. Resistance is overcome by genetic or pharmacological inhibition of GLI1, revealing a potential strategy to overcome drug resistance in some patients.
To better understand the molecular basis for relapse in our clinical trial ( Fig. 1a and Extended Data Fig. 1 ), we generated resistant cells using head and neck carcinoma FaDu and AML-M5 THP-1 cells, both of which have highly elevated eIF4E and concomitant ribavirin sensitivity 6, 7 . Two forms of drug resistance emerged, characterized by unimpaired growth in clinically achievable ribavirin concentrations and a loss of eIF4E targeting (Fig. 1b, c and Extended Data Fig. 2a-c) . Type I resistant cells (FRI, THPA, THPB) had severely impaired drug uptake, whereas type II resistant cells (FRII) did not ( Fig. 1d and Extended Data Fig. 2d ). Type I resistance was characterized by substantial reduction of adenosine kinase (ADK) (Extended Data Fig. 3a, b ). ADK acts in cellular retention of ribavirin, as unphosphorylated ribavirin is readily exported by the nucleoside transporter ENT1 (also known as SLC29A1; refs 9, 10). Indeed, ADK reduction alone imparts ribavirin resistance (Extended Data Fig. 3c, d) . Analysis of our patient pool indicated that only two patients had features consistent with type I resistance (Extended Data Fig. 3e, f) .
Therefore, we investigated type II resistance. Given that eIF4E was not mutated and was functional in FRII cells (Extended Data Fig. 2e-g) , we examined whether the ribavirin-eIF4E interaction was disrupted, by assessing the ability of eIF4E to immunoprecipitate 3 H-ribavirin ( Fig. 1e ). Although 3 H-ribavirin is enriched ,sixfold in the eIF4E-immunoprecipitated fraction in parental cells, this interaction is lost in FRII cells, despite normal uptake and functional eIF4E.
RNA sequencing (RNA-seq) analysis revealed that 30 transcripts were differentially expressed in FRII cells, including GLI1 messenger RNA, by 21-fold (Extended Data Table 1 ). Consistently, GLI1 protein levels were highly elevated, as was GLI1's target SNAIL (Fig. 1f ). We investigated the clinical relevance of this elevation in our patients treated with ribavirin monotherapy. At relapse, leukaemic blasts had elevated GLI1 mRNA levels for 9 out of 9 patients examined (up to tenfold baseline) ( Fig. 2a ). For instance, GLI1 mRNA and protein levels were elevated at relapse (for example, patients 8 (complete remission (CR)), 11 (partial remission (PR)) and 17 (blast response (BR); Fig. 2a and Extended Data Fig. 4 ; confocal microscopy was used owing to limited material at response). Interestingly, GLI1 levels in patient 17 decreased during response and re-emerged at relapse. Patients 9, 13 and 19, who did not respond clinically or molecularly, had highly elevated GLI1 levels before treatment, 1 relative to healthy individuals or responding patients. Moreover, in our ribavirin and low-dose Ara-C Phase I combination trial, patients A (CR, relapsed at 2 years) and B (CR, relapsed at 9 months) had increased GLI1 levels at relapse ( Fig. 2a and Extended Data Fig. 4 ; these patients are denoted by letters so as not to be confused with ribavirin monotherapy patients, denoted by numbers). For patient C (PR, off treatment owing to a dose-limiting toxicity), GLI1 mRNA levels were unchanged at end of treatment (EOT), consistent with continued remission at that time. Thus, elevated GLI1 is associated with primary and acquired resistance in both ribavirin clinical trials. We observed that type I and type II resistance coexisted in two patients ( Fig. 2 and Extended Data Fig. 3e , f). Whether this occurs in the same cells or whether multiple resistant populations emerge is unknown. We extended these studies to investigate whether GLI1 levels were elevated in patients who failed more commonly used Ara-C therapies ( Fig. 2b ). GLI1 mRNA levels were substantially elevated at relapse relative to diagnosis in 7 out of 9 patients examined. Consistently, analysis of The Cancer Genome Atlas AML data set 11 showed that GLI1 elevation was associated with poor prognosis (Extended Data Fig. 5 ). These data suggest that GLI1 overexpression contributed to drug resistance and clinical relapse in some AML patients.
Next, we investigated whether GLI1 alone imparted drug resistance by generating FaDu and THP1 cells stably overexpressing GLI1 (FaDu-GLI, THP1-GLI; Fig. 2c, d ). Growth of GLI1-overexpressing cells was not substantially affected by levels of ribavirin or Ara-C that impaired growth of controls. Further, GLI1 knockdown re-sensitized FRII cells to ribavirin and Ara-C without affecting growth in the absence of either drug ( Fig. 2e ).
To identify strategies to restore drug sensitivity, we used a clinically approved inhibitor of sonic hedgehog signalling upstream of GLI1, GDC-0449 (ref. 12) (Figs 2d and 3a) . FRII cells were pre-treated with 200 nM GDC-0449 (which is clinically achievable 13 ) and subsequently, 20 mM ribavirin. Notably, GDC-0449 treatment followed by ribavirin led to ,60% reduction in growth relative to untreated FRII cells. GDC-0449 treatment alone did not substantially affect growth in either cell line. Importantly, GDC-0449 treatment also restored sensitivity to clinically relevant Ara-C levels (200 nM). Furthermore, GDC-0449 treatment of FaDu-GLI and THP-GLI cells re-sensitized these to ribavirin and Ara-C (Figs 2d and 3a ). Finally, a direct inhibitor of GLI1, GANT61 (ref. 14) , paralleled the effects of GDC-0449 (Extended Data Fig. 6a ). Thus, type II resistance is reversed by pharmacological inhibition of the sonic hedgehog pathway.
To better understand the molecular basis for resistance, we monitored the ability of eIF4E to immunoprecipitate 3 H-ribavirin as a function of GLI1 status ( Fig. 3b and Extended Data Fig. 6b-d ). Although eIF4Eribavirin complexes were readily detected in controls, they were absent in GLI1-overexpressing cells (Fig. 3b ). Conversely, GDC-0449 treatment or GLI1 knockdown in FRII cells restored ribavirin-eIF4E complexes to control levels (Fig. 3b ). Thus, there is a clear correlation between GLI1 elevation, reduction in eIF4E-ribavirin complexes, and resistance.
Given that resistant cells did not form ribavirin-eIF4E complexes but retained active eIF4E (Figs 1e, 3b and Extended Data Fig. 2e -g), we proposed that ribavirin, and possibly Ara-C, underwent some form of GLI1-dependent modification. The drug-metabolizing UGT1A enzymes had elevated protein levels in FRII cells, thereby suggesting a resistance mechanism (Figs 1f and 4a-c). This was also the case for FaDu-GLI and THP-GLI cells, relative to vector controls (Figs 2d and 4b ). Significantly, GLI1 knockdown or GDC-0449 treatment reduced UGT1A protein levels (Fig. 4a, c) , confirming the correlation between GLI1 and UGT1A protein expression. Note that GLI1 does not increase mRNA levels but rather the protein stability of UGT1As (Extended Data Fig. 6e -h).
To determine the clinical relevance of these observations, we examined UGT1A protein levels during response and relapse using confocal microscopy (Extended Data Fig. 4 ). We observed UGT1A elevation upon 
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relapse; that is, patients 11 (CR), 8 (PR) and 17 (BR) in the ribavirin monotherapy trial and in patients A (CR) and B (CR) in the combination trial. Patient C (PR) had no change in UGT1A levels at EOT, consistent with still being in remission. In patients treated with standard Ara-C therapies, UGT1A protein levels were elevated in 6 out of 7 specimens at relapse relative to diagnosis, and this occurred in the patients with concomitant elevated GLI1 ( Fig. 2b ). There was insufficient material for protein analysis of the remaining two specimens. Next, we used mass spectrometry (MS) to determine whether ribavirin and Ara-C were glucuronidated in resistant cells ( Fig. 4d -i and Extended Data Fig. 7 ). Metabolites were isolated, subjected to hydrophilic chromatography and detected by electrospray ionization-MS. In parental cells, ribavirin diphosphate (RDP) is the major peak ( Fig. 4e , l).
In FRII cells, a new peak emerged with a mass consistent with the ribavirin-glucuronide ( Fig. 4d ). Using collision-induced ion fragmentation, we observed the triazole moiety of ribavirin as a major fragment supporting this as a site of glucuronidation ( Fig. 4j red arrow, and Extended Data Fig. 7a ). Relative peak intensities suggest that there is more ribavirin-glucuronide than RDP ( Fig. 4d ). Notably, GDC-0449 treatments eliminated ribavirin glucuronidation in FRII cells ( Fig. 4f ). GLI1 overexpression in parental cells led to formation of ribavirin-glucuronides ( Fig. 4h) . In vitro glucuronidation studies indicated that specific UGT1As are likely to be important to this process, as is ribavirin phosphorylation (Extended Data Fig. 7 ). Moreover, we observe AraC-glucuronides in FRII but not parental cells, and this modification was lost upon GDC-0449 treatment (Extended Data Fig. 7e 
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glucuronidation were GLI1-dependent, and elimination of the glucuronides by GLI1 inhibition correlated with restored drug sensitivity. We examined the capacity of ribavirin-glucuronides to bind eIF4E. Ribavirin-glucuronide was isolated by hydrophilic chromatography and confirmed by MS/MS (Extended Data Fig. 7c ). Using eIF4E-glutathione S-transferase (GST) immobilized on glutathione agarose, we observed that non-radioactive ribavirin or ribavirin triphosphate (RTP) compete for 3 H-ribavirin-eIF4E complexes, whereas neither the negative control GTP nor the ribavirin-glucuronide did so (Fig. 4m ). Thus, ribavirin glucuronidation impairs its interaction with eIF4E, underpinning resistance.
To further explore the effects of GLI1 inhibition on drug sensitivity, we monitored colony growth of primary AML specimens as a function of GDC-0449 treatment (Fig. 3c ). Specimens were selected from patients that had previously failed induction chemotherapy. We observed that although GDC-0449 has little effect on colony growth alone, it strongly potentiated the effects of Ara-C and ribavirin, presumably by elimination of the respective glucuronides. By contrast, we observed little effect in specimens from healthy volunteers, consistent with our results in control cells.
Several factors probably contribute to GLI1 elevation in FRII cells, including reduced patched 1 levels, but not altered promoter methylation or modified hedgehog ligand levels (Extended Data Fig. 8 ). Glucuronidation is typically perceived as a detoxification pathway but does not always enhance drug excretion 15 . Similar to our findings with ribavirin and eIF4E, testosterone glucuronidation modifies its targets rather than its efflux 15 . Our findings reveal a role for GLI1 in drug metabolism and resistance. Here, GLI1 inhibition could restore drug sensitivity and thereby provide therapeutic benefit.
METHODS SUMMARY
Ribavirin-resistant cell lines were selected on the basis of prolonged ribavirin exposure, routinely tested for resistance, which was retained even after 6 months in the absence of ribavirin. In the absence of ribavirin, cells grew with indistinguishable doubling times (Extended Data Fig. 2) . Drug treatments and cell viability assays were carried out as described 16 using Trypan Blue or in parallel, Cell Counting Kit-8. For 3 H-ribavirin immunoprecipitation, cells were incubated with 0.66 mM 3 H-ribavirin for 8 h at 37 uC, dounce homogenized, lysates pre-cleared and immunoprecipitated with 8 mg mouse IgG or monoclonal mouse anti-eIF4E antibodies coupled to Protein A/G PLUS-Agarose overnight at 4 uC. Beads were washed, subjected to scintillation counting or western analysis.
Quantitative PCR analysis used the relative standard curve method 5 . Western analysis was described 6 with a modified lysis buffer (40 mM HEPES, pH 7.5, 120 mM NaCl, 1 mM EDTA, 10 mM b-glycerophosphate, 50 mM NaF, 0.5 mM NaVO3, and 1% (v/v) Triton X-100 with protease inhibitors). For mass spectroscopy, cells were treated with ribavirin or Ara-C, mixed with an equal volume of methanol, flash frozen in liquid nitrogen, stored at 280 uC overnight, thawed, centrifuged at 10,000 r.p.m. for 10 min and subjected to hydrophilic chromatography (Inertsil HILIC) using an Agilent 1100 HPLC coupled to an Agilent MSD Trap SL, with an ESI source in positive ion mode. Chromatography used 2 mM ammonium formate, pH 3.2 (solvent A) and 100% acetonitrile (solvent B). For 3 H-ribavirin pulldown, eIF4E-GST immobilized on glutathione beads was incubated with 250 nM 3 Hribavirin and the same concentration of purified Rib-Glu, 1 H-ribavirin, RTP, GTP or buffer for 30 min in 100 mM sodium phosphate, pH 7.5, 300 mM NaCl, 0.015% NP40, 10 mM BSA with protease inhibitors. Samples were eluted in Laemmli; radioactivity measured by scintillation counting. Colony formation assays in AML specimens were as described 7 .
Clinical Trials were approved by each institution ethics board and by Health Canada. Written informed consent was obtained according to the Helsinki protocol. Clinical trials were registered with ClinicalTrials.gov NCT00559091 and NCT01056523.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Reagents and constructs. Full-length human GLI1 was obtained from Addgene (K12 Plasmid 16419), subcloned into 2-FLAG-pcDNA3.1 or pMSCV-GFP (bicistronic vector) and the subsequent clones validated by sequencing. Ribavirin was obtained from Kemprotec (CAS 36791-04-5), cytosine b-D-arabinofuranoside (C17680) and GANT61 (G9048) from Sigma Aldrich, vismodegib (GDC-0449, S1082) from Selleckchem, ribavirin-13 C2 ( 13 C on the triazole ring and carboxy amide, TLC-ID # R-041, CAS number 36791-04-5) from TLC PharmaChem, ribavirin [triazole-5- 3 . Antibody specificity for UGT1A and GLI1 is shown in Extended Data Fig. 8 . Results with UGT1A pan antibody above were confirmed with another pan-UGT1A antibody from Santa Cruz sc-25847. The pan-UGT1A antibodies recognize the common carboxy terminus of UGT1As; with UGT1As having approximately the same molecular weight 8 . Importantly, the effects were specific to UGT1A as UGT2B levels were not changed (Extended Data Fig. 6i ). Cell culture and transfection. FaDu cells (ATCC HTB-43) were maintained in MEM supplemented with 1% MEM non-essential amino acids, 10% heat-inactivated FBS and 1% penicillin-streptomycin (Invitrogen). 2FLAG-GLI1 or 2FLAG vector control FaDu cell lines were generated using TransIT-LT1 transfection reagent (Mirus), according to manufacturer guidelines and were selected using geneticin selective antibiotic (G418 Sulphate) (MultiCell). THP1 cells (ATCC TIB202) were maintained in RPMI 1640 (Invitrogen) supplemented with 10% heat-inactivated FBS and 1% penicillin-streptomycin. THP1-GLI cells were generated using pMSCV-GFP as described in ref. 17 . HepG2 cells (ATCC HB-8065) were maintained in DMEM supplemented with 10% heat-inactivated FBS and 1% pencillin-streptomycin (Invitrogen). For RNAi experiments, FaDu and HepG2 cells were transfected with Lipofectamine 2000 (Invitrogen) and 40 nM siRNA duplexes, and were analysed 96 h post-transfection. The following siRNA duplexes were used: siGLI1 (designed by Integrated DNA technology, catalogue number: HSC.RNAI.N005269.12.3_10NM), si_eIF4E sense (CCCAAAUCUCGAUUGCUUGACGCAGUC), si_eIF4E antisense (CUGCGUCAAGCAAUCGAGAUUUGGG), siADK (designed by Integrated DNA technologies, catalogue number HSC.RNAI.N001123.12.5); siUGT1A three sequences were used such that the total amount of the siRNA mix is equal to 40 nM (designed by Integrated DNA technologies, catalogue number HSC.RNAI.N001072.12.2_10NM; HSC.RNAI.N001072.12.10_NM; HSC.RNAI.N007120.12.9_NM), Control duplex: siLuc sense (CACGUACGCGGAAUACUUCGA), siLuc antisense (CAUUUCGAA GUAUUCCGCGUACGUGUU). Generation of ribavirin-resistant cell lines. FaDu or THP-1 cells were exposed to either a single concentration of ribavirin for a prolonged period (for example, 10 mM for FRII cells) or increased concentrations starting at 1 mM and doubling the concentration every 2 weeks until cells became resistant to 100 mM ribavirin (FRI) or starting with 10 and 20 mM ribavirin and doubling the concentration after 2 months (THP-based cells: TR-A and TR-B). Cells were routinely tested for ribavirin resistance. All cell lines (resistant and parental) were routinely checked to ensure there was no mycoplasma contamination using MycoAlert Mycoplasma Detection kit (Lonza, LT07-418). Drug treatments and cell viability assay. These assays were carried out as described previously 16 . In brief, 25 3 10 4 cells per ml were seeded in triplicates/condition in 12-well cell culture plates (BD Biosciences 353043) (except for experiments involving pre-treatments with GDC-0449, where 15 3 10 4 cells per ml were used). To measure the effect of ribavirin on cell growth, cells were treated on the next day with 0, 10, 20, 50 or 100 mM ribavirin. Treatments were repeated every 48 h and cell viability was assessed by Trypan Blue dye exclusion test at each concentration every 24 or 48 h for up to 5 days. The percentage growth inhibition of treated cultures relative to untreated cultures was determined. Further, the ability of GDC-0449 or GANT61 to restore sensitivity to ribavirin or Ara-C was determined by pre-treating cells with 200 nM GDC-0449 or 20-40 mM GANT61 for 6 and 3 days, respectively, followed by treatments with 20 mM ribavirin or 200 nM Ara-C for 4 days. Cell viability was measured as mentioned above. Note that the IC 50 for each of the above mentioned drugs was determined a priori and that all of our cell viability experiments were validated by colorimetric assays using the Cell Counting Kit-8 (Dojindo Molecular Technologies, CK04-11) according to the manufacturer's guidelines. Drug uptake. Cells were plated in triplicates at a density of 0.5 3 10 6 cells per ml in 12-well plates. 24 h later, cells were incubated with 0.66 mM 3 H-ribavirin for 2, 4, 6, 8, 12 and 16 h. After treatment, cells were washed twice with ice-cold PBS and lysed with 2 volumes of NaOH (1N) and then neutralized with equal volume of HCl (1N). Samples were mixed with 5 ml Optiphase 'Hisafe 2' Scintillation cocktail (Perkin Elmer, 1200-436) and radioactivity was measured using a liquid scintillation counter (Tri-Carb 2800 TR, PerkinElmer). eIF4E-3 H-ribavirin immunoprecipitation. Cells were seeded at a density of 1.2 3 10 6 cells per 900 ml of a 6-well plate (BD Biosciences, 353046) (three wells were used per each cell line tested) and incubated with 0.66 mM 3 H-ribavirin for 8 h at 37 uC, 5% CO 2 . Following incubation, cells were washed three times with PBS and scraped in IP buffer (50 mM Tris, pH 5.5, 5 mM EDTA, 150 mM NaCl, 0.5% NP40 and 1% Triton X-100). Cells were then homogenized using a glass Dounce homogenizer and left to rotate at 4 uC for 30 min. After centrifugation at 10,000 r.p.m. for 10 min at 4 uC, supernatants were split into two tubes and pre-cleared with normal mouse-IgG beads (Santa Cruz, sc-2343) for 30 min at 4 uC. After spinning at 500g for 5 min, protein concentrations were quantified using Pierce BCA Protein assay (Thermo Scientific, 23223). 100-200 mg of protein lysates were used for immunoprecipitation with 8 mg of normal mouse IgG (Millipore, 12-371) or mAb mouse anti-eIF4E (P-2) (Santa Cruz, sc-9976) antibodies coupled to Protein A/G PLUS-Agarose (Santa Cruz, sc-2003). Immunoprecipitations were carried out overnight at 4 uC. Beads were washed six times with IP buffer and eluted with 80 ml 23 Laemmli sample buffer (BioRad) for 15 min at 99 uC. After spinning bead supernatants were used for scintillation counting and western analysis (probed with rabbit anti-eIF4E antibody). Deep sequencing. Total RNAs were isolated from different cell lines using Trizol (Invitrogen). Samples were prepared into 50-bp fragment libraries and sequenced on the ABI SOLiD v.3 to obtain an average of 3.2 Gbp of transcript sequences. Data were mapped to the reference genome using the RNaseq pipeline found in the Bioscope software (https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd5 catNavigate2&catID560680, #2). Keeping only uniquely matching reads, we used fragment count per transcript as an estimate of gene expression. We then used the statistical method based on a negative binomial distribution and implemented in the DESeq package 18 for R to compare samples and obtain a robust measure of differential expression between samples. The resulting P values were adjusted for multiple testing with the Benjamin-Hochberg procedure to yield P adj values. Reverse transcription and quantitative PCR. DNase-treated RNA samples (Turbo DNase, Ambion) were reverse transcribed using MMLV reverse transcriptase (Invitrogen) or Supervilo kit (Invitrogen) for primary specimens. qPCR analyses were performed using EXPRESS SYBR GreenER QPCR SuperMix (Invitrogen) in AB StepOne thermal cycler using the relative standard curve method (Applied Biosystems User Bulletin #2). All conditions were described previously 5, 19 . Primers list: GLI1 forward (GGCTGCAGTAAAGCCTTCAGCAAT), GLI1 reverse (TGC AGCCAGGGAGCTTACATACAT), UGT1A forward (ACTGGAACCCGACCA TCGAATCTT), UGT1A reverse (CACCAAACAAGGGCATCATCACCA), UGT1A1 forward (AACAAGGAGCTCATGGCCTCC), UGT1A4 forward (GAAGGAAT TTGATCGCGTTAC), UGT1A6 forward (TCCTGGCTGAGTATTTGGGCC), UGT1A9 forward (GGAGGAACATTTATTATGCCACCG), common UGT1A reverse2 (CCAATGAAGACCATGTTGGGC), UBC forward (ATTTGGGTCG CGGTTCTTG), UBC reverse (TGCCTTGACATTCTCGATGGT), RPIIa forward (TGACTGCCAACACAGCCATCTACT), RPIIa reverse (GGGCCACATCAAA GTCAGGCATTT), G6PDH forward (TGGCAAAGTCGGTTTCTCTCTGGA), G6PDH reverse (TTGGGAACATGTCTCAGACTGGCA), ADK forward (AGA GGCAGCGAATCGTGATCTTCA), ADK reverse (ACCTCCAACAAATGCAT CTCCAGC), ENT1 forward (CTCTCAGTGCCATCTTCAAC), ENT1 reverse (CAGAAACACCAGCAGGATGG). Western blot analysis. Western analysis was performed as described previously with a modified lysis buffer (phospholysis buffer: 40 mM HEPES, pH 7.5, 120 mM NaCl, 1 mM EDTA, 10 mM b-glycerophosphate, 50 mM NaF, 0.5 mM NaVO 3 , and 1% (v/v) Triton X-100 supplemented with complete protease inhibitors (all from Sigma-Aldrich)). In addition, blots were blocked in BSA blocking solution (3% (wt/v) BSA (Sigma-Aldrich) or 5% milk in TBS-Tween 20), and primary antibodies were diluted in BSA blocking solution or 5% milk. Immunofluorescence and laser-scanning confocal microscopy. Immunostaining was carried out as described 5 . In brief, upon methanol fixation (10 min at 220 uC), cells were blocked for 1 h, and incubated with 1u antibodies (1:500 dilution) overnight at 4 uC, followed by three washes in blocking solution. Cells were then incubated with 2u donkey anti-rabbit IgG-Texas Red antibody (Jackson Immunolaboratories, diluted 1:100 in blocking solution), washed four times with 1 3 PBS (pH 7.4) and mounted in Vectashield with DAPI (Vector Laboratories). Analysis was RESEARCH LETTER carried out using a laser-scanning confocal microscope (LSM510 META; Carl Zeiss), exciting 405 and 543 nm or 488 nm with a 3100 objective, 32 digital zoom (where indicated), and numerical aperture of 1.4. Channels were detected separately, with no crosstalk observed. Confocal micrographs represent single sections through the plane of the cell. Images were obtained from LSM510 software version 3.2 (Carl Zeiss) and displayed using Adobe Photoshop CS2 (Adobe). Mass spectroscopy. FaDu, FRII, 2FLAG, 2FLAG-GLI1 or GDC-0449-treated cells grown in culture were trypsinized and put in to suspension at a density of 10 3 10 6 cells per ml media 20 . Concentrations of 1 mM ribavirin mix ( 12 C-ribavirin 1 13 C2ribavirin in a 50:50 ratio) were added in duplicate per condition and samples were incubated in a 37 uC shaker. A 100-ml aliquot was taken at different time points (0, 10, 30, 60, 120, 180, 240, 300 and 360 min) mixed with equal volume of 100% methanol (Fisher Scientific, HPLC grade, A412P-4) and flash frozen in liquid nitrogen. Samples were stored overnight at 280 uC. At the time of analysis, samples were thawed, centrifuged at 10,000 r.p.m. for 10 min and subjected to hydrophilic chromatography in line with mass spectrometer. The system used was an Agilent 1100 HPLC coupled to an Agilent MSD Trap SL, with an ESI source. The autosampler system was kept at 4 uC. The HPLC column was an Inertsil HILIC, 150 3 4.6 mm, 5 mm and the chromatography was obtained using solvent A (2 mM ammonium formate in water, pH 3.2) and solvent B (100% acetonitrile). The injection volume was 50 ml and the flow rate 1 ml per min. The column compartment was heated at 30 uC. The initial gradient was 95% B and 5% A, which changed during a 30-min course to 5% B and 95% A followed by 6 min equilibration at 95% B and 5% A. The total run time of the gradient was 36 min. The ESI source of the coupled MS ion-trap was set in positive ion mode, the nitrogen drying gas flow at 12 ml per min, the nebulizer pressure at 55 PSI and the temperature of the capillary at 350 uC with a voltage of 4,500 V. The mass analyser was set to scan from 50 to 1,500 m/z. For Ara-C glucuronidation assay, the same protocol was applied; however, the initial gradient was ran over a 20 min time course rather than 30 min. Glucuronidation assay. Glucuronidation of ribavirin by human liver microsomes expressing UGT1A1, UGT1A4, UGT1A6 and UGT1A9 was performed as described previously 21 . In brief, 50 mg of pooled human liver microsomes (BD Biosciences, 452116) were incubated with 25 mg alamethicin (Sigma-Aldrich, A4665) and 50 mM Tris-HCl, pH 7.4, containing 10 mM MgCl 2 , for 15 min on ice to allow formation of channels in the microsome membrane thus enabling access to the UGT active sites 17 . Following incubation, 8.5 mM saccharic acid 1,4-lactone (b-glucuronidase inhibitor, Sigma-Aldrich, S0375) and 1 mM ribavirin 59-triphosphate were added and the mixture was incubated at 37 uC for 5 min. Finally, to activate the reaction, 100 mM uridine 59-diphosphoglucuronic acid (UDPGA, Sigma Aldrich, U6751) was combined and incubations were performed at 37 uC for 6 h. Note that no glucuronides were observed in the absence of UDPGA addition (data not shown). All reactions were made in 100 ml final volume and were terminated by the addition of 100 ml cold methanol (100%). The mixtures were kept at 280 uC for at least 3 h, then thawed and centrifuged for 10 min at 10,000 r.p.m. and the resulting supernatants were analysed by hydrophilic chromatography in line with the mass spectrometer, as described above. We note that RTP was clearly glucuronidated in these microsomes whereas ribavirin was not, suggesting that ribavirin needs to be phosphorylated in order to be efficiently or stably glucuronidated. However, this step would be before glucuronidation as we never observed RTP-glucuronide or other phosphorylated form of the ribavirin-glucuronide. Furthermore, we did not observe glucuronidation of RTP in supersomes that express only UGT1A1, suggesting that other UGT1As must be present. Finally, although we observed glucuronidation of Ara-C efficiently in FRII and FaDu-GLI cells, we did not observe it in the microsomes, suggesting that some other UGT1A (than UGT1A1, UGT1A4, UGT1A6 and UGT1A9) needs to be present for efficient glucuronidation. Clearly this family member is well expressed in the FRII and FaDu-GLI cells. Purification of ribavirin-glucuronides. Ribavirin-glucuronide was isolated from our microsomal preparation using the same liquid chromatography method described above with the time course for initial gradient being expanded to 40 min in order to obtain a better separation of the different metabolites. In brief, given that the Rib-Glu peak elutes around 8.9 min, three 500-ml fractions were collected bracketing this time and lyophilized by centrifugation using Sarvant SpeedVacc High Capacity Concentrator (Thermo Scientific, SC210A-115). The materials obtained from lyophilisation were re-suspended in a small volume of water: methanol (50:50 v/v) and an aliquot was reanalysed by HPLC-MS to verify the isolation and purity of the metabolite. To estimate the concentration of the purified Rib-Glu, a standard curve with the metabolite versus ribavirin-13 C2 (used as an internal standard) was generated. The concentration range for the standard curve was from 10 nM to 1 mM. The curves were constructed by plotting the concentration of the internal standard against the area of the analyte. 3 H-ribavirin pulldown. To determine whether Rib-Glu binds eIF4E, we performed an in vitro binding assay. In brief, 10 nM purified recombinant eIF4E-GST protein was coupled to 40 ml glutathione sepharose beads (GE Healthcare Life Sciences, 17-5132-01) for 30 min at room temperature in buffer containing 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 2.5 mM MgCl2, 0.5 mM DTT, 0.015% NP40, 0.5% proteasefree BSA, and protease inhibitors. Washed beads were then incubated with 250 nM 3 H-ribavirin and an equivalent concentration of either purified Rib-Glu, 1 H-ribavirin, RTP, GTP or blank for 30 min at room temperature in a buffer containing 100 mM sodium phosphate, pH 7.5, 300 mM NaCl, 0.015% NP40, 10 mM BSA and protease inhibitors. Washed beads were then eluted in 13 Laemmli sample buffer (containing b-mercaptoethanol) and radioactivity in supernatants was measured by scintillation counting (note that for washing the beads, 100 mM of GTP was added). m 7 G-sepharose affinity chromatography. Cells were harvested from 10-cm plate per condition at 80% confluency and lysed in 2 volumes of buffer B (50 mM MOPS/ KOH, pH 7.4, 100 mM NaCl, 50 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% NP40, 1% Na-DOC, 7 mM b-mercaptoethanol, protease inhibitors and 1 mM Na 3 VO 4 ) on ice for 15 min with occasional vortexing. Lysates were spun at 16,000g for 10 min at 4u C. m 7 GDP-agarose beads (GE Healthcare UK, 275025) were washed in buffer C (50 mM MOPS/KOH, pH 7.4, 100 mM NaCl, 50 mM NaF, 0.5 mM EDTA, 0.5 mM EGTA, 7 mM BME, 2 mM benzamidine or 0.5 mM PMSF, 1 mM Na 3 VO 4 and 0.1mM GTP). Lysates (,500 mg) were diluted to 1 ml with buffer C and added to washed beads (,50 ml of 50% slurry). After incubation of the reactions for 20 min at 4 uC on the rotating wheel, beads were washed at least three times with buffer C and eluted with 23 Laemmli buffer (BioRad). Note that all centrifugation steps are 500g for 1 min at 4 uC. Protein stability. To determine whether GLI1 regulates UGT1A protein's halflife, we investigated the effect of MG132 proteasome inhibitor (Sigma Aldrich) on UGT1A's half-life. Both FRII and wild-type cells were seeded at 70% confluency in 10-cm plates 24 h before treatment. Cells were then treated with 10 mM MG132 or an equivalent volume of methanol as a control. Ten hours post-treatment, cells were harvested and lysed in phospholysis buffer and UGT1A protein stability was assessed by western analysis using a pan-UGT1A antibody. Primary AML specimens and healthy volunteers. A total of 19 patients were enrolled in the study in three participating centres; Jewish General Hospital, Hamilton Health Sciences, and Hôpital Maisonneuve Rosemont. In total, 15 patients were eligible for evaluation. Written informed consent was obtained as per the Helsinki Protocol. This study received IRB (all sites) and Health Canada approval. ClinicalTrials.gov registry is NCT00559091. Clinical response was assessed using the Cheson criteria 22 . Patients had to receive a diagnosis of primary or secondary AML, French-American-British (FAB) subtypes M4 or M5 only, relapsed or refractory after at least one cycle of conventional chemotherapy; or newly diagnosed but not be candidates for induction chemotherapy. Patients must also have been at least 18 years of age and must have had an Eastern Cooperative Oncology Group (ECOG) performance status lower than 3 and a life expectancy of at least 12 weeks. Other requirements were as outlined in ref. 5 . The ribavirin Ara-C combination Phase I trial (Clinicaltrials.gov NCT01056523) is recently completed, and patients with remissions were analysed for GLI1 and UGT1A levels. Criteria were the same as for the monotherapy trial described above. Written informed consent according to the Declaration of Helsinki was obtained from all patients as for the monotherapy trial. For analysis of primary specimens in colony growth assays, specimens were obtained from the Leukaemia Cell Bank of Quebec (BCLQ), with no identifying information. Leukaemic blasts were isolated by flow cytometry as described in ref. 5 . For tissue-matched controls at diagnosis and relapse, patient specimens were collected with written informed consent from either University of Rochester Medical Center RSRB approval and ClinicalTrials.gov NCT01311258 or from the BCLQ. For controls, normal bone marrow, peripheral blood mononuclear cells or normal CD34 1 cells were used as indicated, and were obtained from StemCell Technologies. Protein and RNA were isolated as described (see below). Bone marrow staining. Squash preparations of bone marrow aspirates and touch prints of bone marrow biopsies were air-dried and stained with Wright-Giemsa. To examine the specimens Leica DMLS microscope with the 350 objective oil immersion lens was used. The Infinity 1-2C-184976 camera was used to capture images and images were analysed on the Infinity Analyze image acquisition software (release 5.0.2, 2002-2009 Infinity corporation). Lysozyme staining was as described previously 23 . Images for lysozyme staining were captured Leica DM LB2 microscope, and Leica DFC 350X camera and displayed with Adobe Photoshop 7.0 software. Single-locus DNA methylation assays. Total genomic DNA was extracted from 2 3 10 6 FaDu and FRII cells using the Gentra Puregene cell kit (Qiagen) and eluted in RNase-free water. EpiTYPER assays (Sequenom) were performed on bisulphiteconverted DNA. Bisulphite conversion was performed using EZ DNA Methylation kit from Zymo Research. EpiTYPER primers were designed to cover 29 GLI1 CpGs (25 of them in CpG islands) using Sequenom EpiDesigner beta software (http:// www.epidesigner.com/). Primer sequences are below. EpiTYPER primers. GLI1 forward 1 GGGTTTTGGGGGTGTAATAAGT, GLI1 reverse 1 CCCTAAAAAACTAAACATCCCCTC, GLI1 forward 2 TTTGGGAT GAGTTTTTAAGAAGTTG, GLI1 reverse 2 CCTAAAAATCCTAAAAATACA ATAAACCC. Fig. 1c ). Actin provides a loading control. c, Resistance is retained after 6 months of growth in the absence of ribavirin. d, Incubation of live cells with 3 H-ribavirin indicates that THP-1 resistant cells have impaired uptake of ribavirin similar to FRI cells. e, eIF4E cap binding and eIF4G binding activity are retained in FRII cells.
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f, FRII cells are sensitive to eIF4E knockdown measured by cell growth. g, Effects of RNAi-mediated knockdown of GLI1 or eIF4E on UGT1A levels. Western blots were probed as indicated. RNAi-mediated knockdown of GLI1 led to reduced levels of UGT1A whereas knockdown of eIF4E did not. For UGT1A, a pan-UGT1A antibody was used. Antibody controls for UGT1A and GLI1 are shown in Extended Data Fig. 8c . Results are representative of at least three independent experiments. Average values are reported and error bars indicate 6standard deviations. Experiments were carried out in triplicate, three independent times. Western blots are representative of at least three independent experiments.
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Extended Data Figure 3 | Pro-drug metabolism is impaired in type I resistance. a, b, Western analysis reveals that ADK levels were reduced in FRI cells (a) and THP1 resistant cells (b). Treatments were 48 h at 20 mM ribavirin. c, d, Knockdown of ADK leads to ribavirin resistance as shown by cell growth. Western blot confirms knockdown of ADK. Hsp90 provides a loading control. e, f, ENT1 and ADK mRNA levels for patients' specimens. Patient 11 (CR) was responding clinically at (and before) 84 and 112 days and relapsed around day 252, when both ADK and ENT1 mRNA levels decreased. Analysis of RNA samples isolated before and at the end of the first 28-day cycle for patient 9 (who did not respond to ribavirin) compared to a healthy volunteer. Averaged values for ADK and ENT1 RNAs were normalized to glucose 6-phosphate dehydrogenase (G6PDH). Error bars indicate 6 s.d.; centre values are averages. All experiments were performed in triplicate at least three independent times. **P , 0.01, ***P , 0.001 (two-tailed Student's t-test). Results are representative of at least three independent experiments.
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Extended Data Figure 4 | Confocal micrographs of leukaemic blasts isolated from bone marrows of responding and non-responding patients before treatment, at response or at EOT. Immunostaining for GLI1 and UGT1A are shown. DAPI is in blue. Note nuclear accumulation of GLI1 in non-responding patients, indicating elevated GLI1 activity. High levels of GLI1 and UGT1A suggest primary resistance. All confocal settings were identical between specimens and thus lower signal is indicative of less protein. A 3100 objective with no digital zoom was used for patients 9, 11, 13, 17 and 19. The same objective but a digital zoom of 32 was used for patients 8, A, B and C. Note patient C was still in remission at EOT (see main text). For each patient, staining was carried out three independent experiments. Controls for specificity of GLI1 and UGT1A antibodies are provided in Extended Data Fig. 8c .
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